Eosinophilic Esophagitis Market Expected to Exceed USD 1.8 Billion by 2034 with Nearly 65% of Diagnosed Patients Located in the US, analyses DelveInsight

Eosinophilic Esophagitis Companies are Ellodi Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others.
The Eosinophilic Esophagitis treatment market across the 7MM was valued at approximately USD 1.8 billion in 2023 and is expected to grow steadily through 2034. The United States accounts for the largest share of diagnosed prevalent cases (around 65% in 2023), with prevalence higher in adults and males across all major markets.

Within Europe, Germany is projected to generate the highest revenue by 2034, followed by France and the UK. Proton pump inhibitors remain the foundation of treatment, while newer biologics and corticosteroid formulations such as DUPIXENT, EOHILIA, and JORVEZA have strengthened the therapeutic landscape.

The pipeline remains robust with emerging candidates including VELSIPITY, TEZSPIRE, ESO-101, and Cendakimab. Recent regulatory milestones such as FDA approvals of EOHILIA and expanded pediatric indications for DUPIXENT in the US and Europe are expected to further drive market growth during the forecast period.

DelveInsight's "Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive overview of the disease, covering historical and projected epidemiology along with evolving market trends across the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report analyzes current standards of care, emerging therapies, and the market share of key treatments, while presenting the historical and forecasted Eosinophilic Esophagitis market size from 2020 to 2034 across the seven major markets. It also examines treatment algorithms, key market drivers and restraints, unmet medical needs, and growth opportunities, offering insights into the overall potential of the Eosinophilic Esophagitis market

To Know in detail about the Eosinophilic Esophagitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Eosinophilic Esophagitis Market Report:

* The Eosinophilic Esophagitis Treatment Market Size in the 7MM was approximately USD 1,800 million in the 2023, which is expected to grow during the forecast period (2020-2034).
* In June 2025, Sanofi announced results of a Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE)
* In May 2025, Celldex Therapeutics announced results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults With Active Eosinophilic Esophagitis (The "EvolvE" Study)
* In May 2025, Astrazeneca announced results of a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
* In May 2025, Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere Trademark technology designed to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader (KOL) event on Friday, May 9, 2025 at 9:00 AM ET
* In February 2025, Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotech firm focused on precision local drug delivery, today shared further positive clinical results from its ongoing RESOLVE Phase 1b/2a trial, which is assessing EP-104GI for the treatment of eosinophilic esophagitis (EoE).
* In December 2024, Holoclara, a biotech firm focused on worm-derived therapies for allergic and autoimmune diseases, has chosen eosinophilic esophagitis (EoE) as the primary indication for its investigational drug, HC002, with plans to expand to other conditions. The company is currently conducting a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of HC002 in healthy adults.
* In December 2024, Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotech company developing innovative biologics for inflammatory and immunology (I&I) conditions, including atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE), has announced the start of dosing healthy volunteers in its clinical trial of APG333. This novel, subcutaneous monoclonal antibody, with a half-life extension, targets thymic stromal lymphopoietin (TSLP) and is initially being evaluated as a treatment for asthma, COPD, and other I&I disorders.
* In September 2024, Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of DUPIXENT (dupilumab) in the European Union for EoE in children down to 1 year of age. The recommendation is for children aged 1-11 years who weigh at least 15 kg. The European Commission is expected to announce a final decision in the coming months.
* In February 2024, Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
* In January 2024, The US FDA granted approval for DUPIXENT (dupilumab) to treat pediatric patients between the ages of 1 and 11 years, weighing at least 15 kg, who have eosinophilic esophagitis (EoE). This approval stems from the Phase III EoE KIDS trial, which demonstrated that a higher percentage of children receiving DUPIXENT achieved histological remission compared to those receiving a placebo.
* There are few approved medications available in the market to treat eosinophilic esophagitis (EoE), including DUPIXENT (dupilumab) and JORVEZA (budesonide).
* In 2023, the overall diagnosed prevalent cases of eosinophilic esophagitis (EoE) were estimated to be around 800,000 across the Seven Major Markets (7MM). These numbers are projected to experience moderate growth at a compound annual growth rate (CAGR) by the year 2034.
* In 2023, within the Seven Major Markets (7MM), the United States reported the highest number of diagnosed prevalent cases of eosinophilic esophagitis (EoE), totaling nearly 500,000 cases.
* Based on DelveInsight's analysis, the greatest number of diagnosed cases of eosinophilic esophagitis (EoE) were observed in Germany, with France following closely behind among the EU4 and the UK in 2023. It is anticipated that these numbers will rise throughout the forecast period from 2024 to 2034.
* According to the National Organisation of Rare Disorders (NORD), 1 in 2,000 people are thought to be affected by eosinophilic esophagitis
* With 319,429 Eosinophilic Esophagitis cases in 2020, the United States had the most cases among the 7 MM countries
* Key Eosinophilic Esophagitis Companies: Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Celgene, Oxagen Ltd, Meritage Pharma, Inc, Forest Laboratories, and others
* Key Eosinophilic Esophagitis Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, reslizumab, CC-93538, Mesalamine, IRL201104, budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide plus Prevacid, EUR-1100, and others
* The Eosinophilic Esophagitis epidemiology based on gender analyzed that Eosinophilic Esophagitis affects more males as compared to females
* The Eosinophilic Esophagitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Eosinophilic Esophagitis pipeline products will significantly revolutionize the Eosinophilic Esophagitis market dynamics.

Eosinophilic Esophagitis Overview

Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the esophagus characterized by eosinophil infiltration, leading to symptoms such as dysphagia, food impaction, chest pain, and feeding difficulties. It is commonly associated with allergic conditions and shows a higher prevalence in males and adults. Diagnosis relies on endoscopy and histological evaluation. Management focuses on dietary modification, proton pump inhibitors, topical corticosteroids, and biologic therapies. With increasing awareness, improved diagnostics, and the introduction of targeted treatments, the EoE therapeutic landscape continues to evolve across major global markets.

Get a Free sample for the Eosinophilic Esophagitis Market Report: [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Eosinophilic Esophagitis Epidemiology

In the 7MM, the United States reported the highest burden of Eosinophilic Esophagitis in 2023, with approximately 445,000 diagnosed prevalent cases, a figure expected to rise over the forecast period. The disease shows a clear male predominance, with around 290,000 diagnosed males compared to 156,000 females in the US. Additionally, adults over 18 years of age represent the most affected population, accounting for about 156,000 cases in 2023.

Eosinophilic Esophagitis Epidemiology Segmentation:

The Eosinophilic Esophagitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Eosinophilic Esophagitis
* Prevalent Cases of Eosinophilic Esophagitis by severity
* Gender-specific Prevalence of Eosinophilic Esophagitis
* Diagnosed Cases of Episodic and Chronic Eosinophilic Esophagitis

Download the report to understand which factors are driving Eosinophilic Esophagitis epidemiology trends @ [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Eosinophilic Esophagitis Drugs Uptake and Pipeline Development Activities

Cendakimab (CC-93538/RPC4046) - Bristol Myers Squibb

Cendakimab is a humanized monoclonal antibody targeting interleukin-13 (IL-13), designed to block its interaction with IL-13 receptors and potentially enhance efficacy and safety. The therapy has received Orphan Drug Designation from the US FDA for Eosinophilic Esophagitis. Following encouraging Phase II results, Bristol Myers Squibb is currently conducting two Phase III trials to assess its efficacy and safety in adolescent and adult EoE patients.

TEZSPIRE (Tezepelumab) - AstraZeneca/Amgen

TEZSPIRE is a first-in-class monoclonal antibody that inhibits thymic stromal lymphopoietin (TSLP), a key upstream driver of inflammatory pathways. Already approved globally for severe asthma, tezepelumab is being evaluated for multiple inflammatory conditions, including EoE. The drug received FDA Orphan Drug Designation for EoE in October 2021, supporting its potential as a novel treatment option in this indication.

Eosinophilic Esophagitis Therapies and Key Companies

* Dupilumab: Regeneron Pharmaceuticals/Sanofi
* Cendakimab: Bristol-Myers Squibb
* APT-1011: Ellodi Pharmaceuticals
* Benralizumab: AstraZeneca
* Lirentelimab: Allakos
* ESO-101: EsoCap AG
* Etrasimod: Pfizer
* reslizumab: Ception Therapeutics
* CC-93538: Celgene
* Mesalamine: Dr. Falk Pharma GmbH
* IRL201104: Revolo Biotherapeutics
* budesonide: Shire
* QAX576: Novartis
* Florence: EMS
* RPC4046: Celgene
* OC000459: Oxagen Ltd
* Budesonide plus Prevacid: Meritage Pharma, Inc
* EUR-1100: Forest Laboratories

Discover more about therapies set to grab major Eosinophilic Esophagitis market share @ [https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Eosinophilic Esophagitis Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Eosinophilic Esophagitis Companies: Pfizer (NYSE: PFE), Novartis (SWX: NOVN), Allakos (NASDAQ: ALLK), Dr. Falk Pharma GmbH (Private), Regeneron Pharmaceuticals (NASDAQ: REGN), EMS (BVMF: EMSA3), Bristol-Myers Squibb (NYSE: BMY), Revolo Biotherapeutics (Private), Sanofi (EPA: SAN), Oxagen Ltd (Private), Ellodi Pharmaceuticals, AstraZeneca (LSE: AZN), Celgene (NASDAQ: CELG), Forest Laboratories (NYSE: FRX), Shire (NASDAQ: SHPG), Ception Therapeutics (Acquired, formerly private), Meritage Pharma, Inc. (Acquired, formerly private), and others.
* Key Eosinophilic Esophagitis Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, reslizumab, CC-93538, Mesalamine, IRL201104, budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide plus Prevacid, EUR-1100, and others
* Eosinophilic Esophagitis Therapeutic Assessment: Eosinophilic Esophagitis current marketed and Eosinophilic Esophagitis emerging therapies
* Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis market drivers and Eosinophilic Esophagitis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Eosinophilic Esophagitis Unmet Needs, KOL's views, Analyst's views, Eosinophilic Esophagitis Market Access and Reimbursement

To know more about Eosinophilic Esophagitis companies working in the treatment market, visit @ [https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Eosinophilic Esophagitis Market Report Introduction

2. Executive Summary for Eosinophilic Esophagitis

3. SWOT analysis of Eosinophilic Esophagitis

4. Eosinophilic Esophagitis Patient Share (%) Overview at a Glance

5. Eosinophilic Esophagitis Market Overview at a Glance

6. Eosinophilic Esophagitis Disease Background and Overview

7. Eosinophilic Esophagitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Eosinophilic Esophagitis

9. Eosinophilic Esophagitis Current Treatment and Medical Practices

10. Eosinophilic Esophagitis Unmet Needs

11. Eosinophilic Esophagitis Emerging Therapies

12. Eosinophilic Esophagitis Market Outlook

13. Country-Wise Eosinophilic Esophagitis Market Analysis (2020-2034)

14. Eosinophilic Esophagitis Market Access and Reimbursement of Therapies

15. Eosinophilic Esophagitis Market Drivers

16. Eosinophilic Esophagitis Market Barriers

17. Eosinophilic Esophagitis Appendix

18. Eosinophilic Esophagitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-esophagitis-market-expected-to-exceed-usd-18-billion-by-2034-with-nearly-65-of-diagnosed-patients-located-in-the-us-analyses-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.